We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Illumina Announces Scale-Up of Genome Analyzers at the Broad Institute

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute
Illumina, Inc. has announced that the Broad Institute has purchased 30 additional Genome Analyzers, increasing its total installed base of Illumina systems to 89.

“We’ve significantly expanded our fleet of Genome Analyzers to ramp up our sequencing capabilities in whole genome, whole exome, and whole transcriptome analysis,” said Robert Nicol, director of Sequencing Operations at the Broad Institute. “We are happy with the technology’s accuracy, ease of use and scalability, as well as continued system improvements that have recently enabled us to generate multiple runs with more than 50 gigabases of high quality sequence data.”

“This latest purchase by the Broad Institute is another strong vote of confidence in Illumina’s Genome Analyzer technology and its capacity to evolve to meet the future needs of one of the world’s leading genome centers,” said Matt Posard, vice president of Worldwide Sales at Illumina. “We continue to focus our innovation on simplifying workflow, enhancing scalability and increasing high-quality runs, as the scope of genetic research expands dramatically.”

Designed for facilities of all sizes, the Illumina Genome Analyzer has been adopted across genome centers worldwide, plus individual research labs, core and service facilities, and biotechnology and pharmaceutical companies. The Genome Analyzer offers the highest rate of daily output and user-friendly workflow.

The Genome Analyzer also offers the broadest set of supported applications, including whole transcriptome profiling and discovery, epigenetic studies, whole genome resequencing, de novo sequencing, targeted resequencing, ChIP-sequencing, bi-sulfite sequencing (DNA methylation), small RNA, mRNA, tag profiling and metagenomics.